### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Yong-Li Ruan et al.

Application No.: 10/003,405

Filing Date:

December 6, 2001

Group Art Unit: 1638

Examiner: RUSSELL KALLIS

Confirmation No.: 5391

Title: MODIFICATION OF SUCROSE SYNTHASE GENE EXPRESSION IN PLANT TISSUE AND USES

**THEREFOR** 

## THIRD INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:						
PTC		losed is a l9 for the abov	THIRD e-identified pate		sclosure Statement and	accompanying form
	that	The fee of \$1 A statement to \$1.17(p) are Charge A check in the Charge Director is her	80.00 (1806) a inder 37 C.F.R. inder 37 C.F.R. also enclosed.  to Deperamount of to created by this pape	§ 1.97(e) is also er § 1.97(e), and the posit Account No. 02 § 180.00 is encloadit card. Form PT to charge any appr	F.R. § 1.17(p) is also en inclosed. fee of \$180.00 (1806) 2-4800 for the fee due. issed for the fee due. iO-2038 is attached.	nclosed.  as set forth in 37 C.F.R  C.F.R. §§ 1.16, 1.17 and sit Account No. 02-4800
				Res	pectfully submitted,	
				BUF	RNS, DOANE, SWEÇK	ER & MATHIS, L.L.P.
Alex	and	( 1404 ria, Virginia 22 6-6620	313-1404	Ву	Eric H. Weisblatt	oske
Date	e: A	pril 29, 2005			Registration No. 30,5	505

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APR 2 9 200

In re Patent Application of

Yong-Li Ruan et al.

Application No.: 10/003,405

Filed: December 6, 2001

MODIFICATION OF SUCROSE For:

SYNTHASE GENE EXPRESSION IN

PLANT TISSUE AND USES

**THEREFOR** 

Group Art Unit: 1638

Examiner: RUSSELL KALLIS

Confirmation No.: 5391

#### THIRD INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted after a first Office Action on the merits but prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

A fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is enclosed.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:

Eric H. Weisblatt

Registration No. 30,505

Date April 29, 2005\_

P.O. Box 1404 Alexandria, Virginia 22313-1404

(703) 836-6620

05/03/2005 MBEYENE1 00000002 10003405

02 FC:1806

180.00 OP

# Substitute for form 1449A/PTO & 1449B/PTO THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/003,405

Filing Date December 6, 2001

First Named Inventor Yong-Li Ruan et al.

Examiner Name RUSSELL KALLIS

Attorney Docket Number 021565-110

Sheet 1 of 1

U.S. PATENT DOCUMENTS						
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)		
011	13.0					
400 g g	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~					
APR 2 9	ZUID					
TRADE	MARKO					

FOREIGN PATENT DOCUMENTS											
							ST	TATUS			
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Spec
						ļ		ļ	<u> </u>		

	NON-PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=349737; 27/04/2005
	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=19099; 27/04/2005
	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=20373; 27/04/2005
	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=21341; 27/04/2005
	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=169571; 27/04/2005
	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=514945; 27/04/2005
	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=4733945; 27/04/2005
	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=1488569; 27/04/2005
	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=406316; 27/04/2005
	http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=22037; 27/04/2005

Examiner Date	
Signature Considered	there a situation if not in

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.